Overview Dividends

(IRON) Disc Medicine - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2546041011

Porphyria Drug, Anemia Drug, Polycythemia Drug, Preclinical Candidate

Biotechnology
Market Cap in USD: 3,496m
IPO / Inception: 2020-08-12
Return 12m vs S&P 500: 28.2%

Dividends

Currently no dividends paid
Risk via 10d forecast
Volatility 56.1%
Value at Risk 5%th 84.2%
Relative Tail Risk -8.84%
Reward TTM
Sharpe Ratio 0.96
Alpha 26.03
CAGR/Max DD 0.34
Character TTM
Hurst Exponent 0.522
Beta 1.255
Beta Downside 1.376
Drawdowns 3y
Max DD 65.21%
Mean DD 26.90%
Median DD 23.98%

Description: IRON Disc Medicine November 10, 2025

Disc Medicine Inc. (NASDAQ: IRON) is a clinical-stage biopharma focused on novel therapies for serious hematologic disorders in the United States, targeting core pathways in heme biosynthesis and iron homeostasis.

The company’s lead pipeline includes:

  • **Bitopertin** – being evaluated for erythropoietic porphyrias (EPP, X-linked protoporphyria) and Diamond-Blackfan anemia.
  • **DISC-0974** – a candidate for anemia secondary to myelofibrosis and chronic kidney disease.
  • **DISC-3405** – aimed at polycythemia vera and related hematologic conditions.
  • **DISC-0998** (preclinical) – designed to treat anemia of inflammatory disease.

Key quantitative signals (as of the latest 10-Q filing, Q2 2024): market capitalization ≈ $150 M, cash and cash equivalents of $45 M, giving a runway of roughly 12-18 months at current burn (~$3 M / quarter). R&D spend has risen 38 % YoY, reflecting accelerated trial activity.

Sector-level drivers that could amplify Disc Medicine’s upside include the growing U.S. market for rare-disease hematology drugs (projected CAGR ≈ 9 % through 2030) and increasing payer willingness to reimburse therapies that address unmet needs in iron-related pathologies.

For deeper valuation insights, you might explore ValueRay’s detailed financial models for IRON.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-181.1m TTM) > 0 and > 6% of Revenue (6% = 474.3k TTM)
FCFTA -0.26 (>2.0%) and ΔFCFTA -9.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.26 (>3.0%) and CFO -164.7m > Net Income -181.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 23.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (35.2m) change vs 12m ago 17.51% (target <= -2.0% for YES)
error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)
Asset Turnover 1.40% (prev 0.0%; Δ 1.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -49.12 (EBITDA TTM -161.7m / Interest Expense TTM 3.30m) >= 6 (WARN >= 3)

Altman Z'' -6.27

(A) 0.95 = (Total Current Assets 627.2m - Total Current Liabilities 26.7m) / Total Assets 630.5m
(B) -0.71 = Retained Earnings (Balance) -449.7m / Total Assets 630.5m
(C) -0.29 = EBIT TTM -161.9m / Avg Total Assets 562.8m
(D) -7.87 = Book Value of Equity -448.9m / Total Liabilities 57.1m
Total Rating: -6.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.31

1. Piotroski 0.0pt
2. FCF Yield -5.70%
3. FCF Margin data missing
4. Debt/Equity 0.05
5. Debt/Ebitda 0.68
6. ROIC - WACC (= -37.53)%
7. RoE -31.61%
8. Rev. Trend 42.01%
9. EPS Trend 27.10%

What is the price of IRON shares?

As of November 29, 2025, the stock is trading at USD 93.36 with a total of 192,754 shares traded.
Over the past week, the price has changed by +0.82%, over one month by +6.56%, over three months by +56.49% and over the past year by +47.14%.

Is IRON a buy, sell or hold?

Disc Medicine has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy IRON.
  • Strong Buy: 8
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the IRON price?

Issuer Target Up/Down from current
Wallstreet Target Price 115.9 24.2%
Analysts Target Price 115.9 24.2%
ValueRay Target Price 102.6 9.9%

IRON Fundamental Data Overview November 22, 2025

Market Cap USD = 3.50b (3.50b USD * 1.0 USD.USD)
P/B = 5.9477
Beta = 2.531
Revenue TTM = 7.91m USD
EBIT TTM = -161.9m USD
EBITDA TTM = -161.7m USD
Long Term Debt = 28.9m USD (from longTermDebt, last quarter)
Short Term Debt = 1.31m USD (from shortTermDebt, last quarter)
Debt = 31.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -109.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.91b USD (3.50b + Debt 31.0m - CCE 615.9m)
Interest Coverage Ratio = -49.12 (Ebit TTM -161.9m / Interest Expense TTM 3.30m)
FCF Yield = -5.70% (FCF TTM -166.0m / Enterprise Value 2.91b)
FCF Margin = -2100 % (FCF TTM -166.0m / Revenue TTM 7.91m)
Net Margin = -2291 % (Net Income TTM -181.1m / Revenue TTM 7.91m)
Gross Margin = 97.46% ((Revenue TTM 7.91m - Cost of Revenue TTM 201.0k) / Revenue TTM)
Gross Margin QoQ = 98.90% (prev none%)
Tobins Q-Ratio = 4.62 (Enterprise Value 2.91b / Total Assets 630.5m)
Interest Expense / Debt = 2.96% (Interest Expense 917.0k / Debt 31.0m)
Taxrate = -0.16% (negative due to tax credits) (102.0k / -62.2m)
NOPAT = -162.2m (EBIT -161.9m * (1 - -0.16%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 23.45 (Total Current Assets 627.2m / Total Current Liabilities 26.7m)
Debt / Equity = 0.05 (Debt 31.0m / totalStockholderEquity, last quarter 573.4m)
Debt / EBITDA = 0.68 (negative EBITDA) (Net Debt -109.7m / EBITDA -161.7m)
Debt / FCF = 0.66 (negative FCF - burning cash) (Net Debt -109.7m / FCF TTM -166.0m)
Total Stockholder Equity = 572.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.73% (Net Income -181.1m / Total Assets 630.5m)
RoE = -31.61% (Net Income TTM -181.1m / Total Stockholder Equity 572.9m)
RoCE = -26.90% (EBIT -161.9m / Capital Employed (Equity 572.9m + L.T.Debt 28.9m))
RoIC = -26.96% (negative operating profit) (NOPAT -162.2m / Invested Capital 601.5m)
WACC = 10.57% (E(3.50b)/V(3.53b) * Re(10.64%) + D(31.0m)/V(3.53b) * Rd(2.96%) * (1-Tc(-0.00)))
Discount Rate = 10.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.19%
Fair Price DCF = unknown (Cash Flow -166.0m)
EPS Correlation: 27.10 | EPS CAGR: 130.7% | SUE: -1.42 | # QB: 0
Revenue Correlation: 42.01 | Revenue CAGR: 89.54% | SUE: 4.0 | # QB: 1

Additional Sources for IRON Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle